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Between 1998 and 2003, 214 people with Hodgkin’s lymphoma and 214 controls randomly selected from population registers in the
north of England (after matching for age and sex) were recruited and their primary care medical records examined for details of
clinical diagnoses due to infectious and non-infectious conditions in the preceding 15 years. In the year before diagnosis of Hodgkin’s
lymphoma, almost all cases (99%) visited their general practitioner (GP) at least once. In comparison with controls, the excess was
evident both for visits with an infection (odd’s ratio (OR)¼2.1; 95% confidence interval (CI) 1.4–3.2) and for visits with non-
infectious problems (OR¼17.2; 95% CI 6.7–43.9). During the rest of the 15-year period prior to diagnosis, the proportion of people
visiting their GP with a non-infectious condition did not differ between cases and controls. In contrast, compared to controls, there
was an excess of cases visiting the GP with an infection, a finding that was evident for at least a decade prior to diagnosis and
increased linearly with time (P¼0.02). This excess was not due to a specific infection(s) and may reflect underlying immune
abnormality. Alternatively, infection may cause B-cell proliferation from which a malignant clone may evolve.
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The cause(s) of Hodgkin’s lymphoma are largely unknown,
although various infectious and immune factors have been
implicated. A proportion is thought to be related to infection with
Epstein Barr virus (EBV), which is integrated clonally into tumour
cells in as many as 40% of cases (IARC, 1997). Elevated titres of
antibodies against EBV have been associated with subsequent risk
of Hodgkin’s lymphoma, while infectious mononucleosis, known
to be caused by EBV, is an established risk factor (Mueller et al,
1989; Hjalgrim et al, 2000, 2007). Elevated titres of antibodies
against another human herpesvirus (type 6) have been found in
some, but not in other studies (Clark et al, 1990; Jarrett et al, 1998;
Berrington de Gonza ´lez et al, 2006). Infection with human
immunodeficiency virus (HIV) may account for a small proportion
of cases, although the virus is not thought to have any direct
oncogenic activity, but rather to facilitate tumorigenesis via its
immune effects (IARC, 1996; Beral and Newton, 1998; Newton
et al, 1999). Immunosuppression, whether related to HIV infection
or drug treatment such as that experienced by transplant
recipients, appears to be associated with a modest increase in risk
of Hodgkin’s lymphoma – substantially less than that of non-
Hodgkin’s lymphoma (Kinlen et al, 1979; Birkeland et al, 1995;
International Collaboration on HIV and Cancer, 2000; Vajdic et al,
2006). No other specific infectious or immune factors have been
consistently found.
Unravelling any relationship between risk of Hodgkin’s
lymphoma and previous infections is not straightforward. To
investigate the patterns of infectious illness prior to diagnosis, as
well as to identify specific infectious exposures, we systematically
abstracted data compiled prior to diagnosis from primary health-
care medical records. We report here, on the role of clinically
diagnosed infections (as recorded in primary care medical records)
in the aetiology of Hodgkin’s lymphoma.
METHODS
Details of the study are described elsewhere (Willett and Roman,
2006; Willett et al, 2007). Briefly, cases were patients residing in the
north of England between the ages of 16 and 69 years, with newly
diagnosed (non-HIV-related) Hodgkin’s lymphoma, during 1998–
2003. Diagnoses were confirmed pathologically and coded accord-
ing to the World Health Organisation Classification (http://
www.who.int/classifications/icd/adaptations/oncology/en/). For a
proportion of cases, EBV status of the tumour was assessed by in
situ hybridisation for the presence of EBV-EBER in Reed-
Sternberg cells (Willett et al, 2007). For each case, one control
was randomly selected from population registers after matching
for age, sex, and region of residence. At interview, cases and
controls were asked to consent for their primary care medical
records to be accessed by the study team. All information
contained within these routinely compiled health records for the
15 years prior to diagnosis in cases (or pseudo-diagnosis in
controls) was abstracted onto specially designed forms by trained
research staff.
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aneously by the patient’s general practitioner (GP) (i.e. their
primary care physician), as well as all signs and symptoms
recorded at the time, referrals to hospital or other specialists,
results of all investigations, and details of medicines or other
prescribed therapies. Data collection and entry were structured
around dated ‘events’. Disease and drug coding was done centrally
by experienced primary care research nurses, using a specially
designed computerised system embedded within the data entry
programme. Illnesses and symptoms were coded according to the
International Statistical Classification of Diseases and Related
Health Problems (ICD-10), tenth revision (http://www.who.int/
classifications/icd/en/), and drugs to a schema based on the British
National Formulary (http://www.bnf.org/bnf/). Strict quality con-
trol procedures, including duplicate data entry of a proportion of
randomly selected records, were carried out throughout the study
period.
Face-to-face interviews were conducted with 284 (79%) of 360
people with Hodgkin’s lymphoma diagnosed in the study region
and 240 (73%) of 331 controls. Of those, primary care records were
accessed for 214 cases and 214 controls – analyses presented here
are restricted to these individuals. Ethical approval for the study
was granted by the United Kingdom Multi-Regional Ethics
Committee.
Analyses were performed using STATA version 9.2 (http://
www.stata.com) and R version 2.5.1. (http://www.R-project.org).
Data are presented in the form of monthly proportions of patients
making at least one visit to their GP for infectious and non-
infectious conditions over the 15-year period prior to diagnosis (or
pseudo-diagnosis for controls). These proportions were modelled
using unconditional logistic regression with time, case–control
status, and the time–status interaction as explanatory variables.
To prevent the results being skewed by symptoms of disease,
events in the 12 months leading to lymphoma diagnosis (pseudo-
diagnosis for controls) are excluded. In addition, monthly counts
of visits to the GP and of individual diagnoses, were modelled by a
negative binomial general linear model (with logarithmic link
function), but since the results and conclusions did not materially
change, these data are not shown. In disease-specific analyses,
odds ratios (OR) and 95% confidence intervals (CI) were estimated
using unconditional logistic regression with adjustment for sex
and age at diagnosis (in single years).
RESULTS
Of the 214 cases of Hodgkin’s lymphoma, 202 (94%) were
characterised as classical Hodgkin’s lymphoma (CHL) and 12
(6%) as nodular lymphocyte predominant Hodgkin’s lymphoma.
Epstein Barr virus status was available for 144 cases, of which 45
(31%) were positive. In the analyses described below, data for
classical and nodular lymphocyte predominant Hodgkin’s lym-
phoma are combined. Sixty-three per cent of cases were male and
the percentage of cases in age groups 16–29, 30–39, 40–49, and
50–69 was 22, 30, 22, and 26% respectively.
Table 1 shows the number of cases and controls visiting their GP
at least once per year for an infectious or non-infectious condition
during the 15 years prior to diagnosis of Hodgkin’s lymphoma (or
pseudo-diagnosis for controls). In all the time periods, about twice
as many controls visited at least once a year with a non-infectious
condition as compared with an infectious condition. In addition,
the proportion of controls visiting a GP at least once increased
steadily over time, reflecting the effect of ageing. This trend was
driven largely by the proportion visiting for clinical problems
other than infections – there was no statistically significant change
in the proportion visiting for infection over time.
As expected, in the year before diagnosis of Hodgkin’s
lymphoma, almost all cases (99%) visited their GP at least once.
In comparison with controls, the excess was evident both for visits
with an infection (OR¼2.1; 95% CI 1.4–3.2) and, more markedly,
for visits with other non-infectious problems (OR¼17.2; 95% CI
6.7–43.9), including general tiredness and malaise. The total
number of visits in the year prior to diagnosis (or pseudo-
diagnosis) was 1792 for cases and 824 for controls.
Data on the number of patients visiting the GP at least once with
an infection or other condition among cases (in red) and controls
(in blue) are displayed graphically by individual month for the
entire time period (excluding the year prior to diagnosis or
pseudo-diagnosis) in Figures 1 and 2. The model predictions are
shown in the same figure, along with 95% confidence intervals
(dashed lines). In accordance with Table 1, for non-infections
(Figure 1), there is a gradual increase in the proportion of cases
and controls visiting the GP with advancing age, but no differences
between the two groups are evident. In contrast, although the
proportion of controls visiting the GP at least once per month with
an infection varied little over time (P¼1.0; Figure 2), for cases,
Table 1 Number of cases and controls visiting the general practitioner at least once for an infectious or non-infectious condition during each of the 15
years prior to diagnosis of Hodgkin’s lymphoma (or pseudo-diagnosis in controls)
Consultations
All visits Infectious diagnosis Non-infectious diagnosis
Years before diagnosis Controls N (%) Cases N (%) Controls N (%) Cases N (%) Controls N (%) Cases N (%)
1 164 (77) 212 (99) 69 (32) 106 (50) 153 (72) 209 (98)
2 169 (79) 177 (83) 79 (37) 90 (42) 157 (73) 168 (79)
3 177 (83) 180 (84) 77 (36) 89 (42) 166 (78) 164 (77)
4 160 (75) 180 (84) 67 (31) 92 (43) 146 (68) 166 (78)
5 160 (75) 171 (80) 72 (34) 91 (43) 151 (71) 156 (73)
6 164 (77) 161 (75) 80 (37) 82 (38) 144 (67) 139 (65)
7 164 (77) 159 (74) 70 (33) 78 (36) 147 (69) 148 (69)
8 166 (78) 155 (72) 75 (35) 88 (41) 148 (69) 138 (64)
9 168 (79) 161 (75) 80 (37) 77 (36) 140 (65) 148 (69)
10 164 (77) 155 (72) 67 (31) 91 (43) 151 (71) 134 (63)
11 156 (73) 153 (72) 66 (31) 91 (43) 143 (67) 133 (62)
12 152 (71) 155 (72) 75 (35) 89 (42) 132 (62) 133 (62)
13 144 (67) 157 (73) 76 (36) 72 (34) 123 (57) 143 (67)
14 145 (68) 147 (69) 74 (35) 76 (36) 119 (56) 129 (60)
15 137 (64) 138 (65) 64 (30) 68 (32) 120 (56) 119 (56)
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prior to diagnosis (P¼0.02). This excess among cases as compared
to controls did not appear to be due to a specific infection. Data for
the most frequently diagnosed infections, together with some that
have been linked to Hodgkin’s lymphoma in previous studies
(such as herpesvirus infections), are shown for the entire time
period (excluding the year before diagnosis or pseudo-diagnosis)
in Table 2. With the possible exception of herpesviruses and lower
respiratory tract infections, no single infection was particularly
associated with Hodgkin’s lymphoma. The analyses described in
Table 2 were repeated, limiting to infections occurring within 10
years prior to diagnosis (but omitting the year before diagnosis)
and it made no material difference to the findings (data not
shown).
When analyses were restricted to CHL alone, there was no
material difference in the results. Similarly, when analyses were
stratified by age (o40 and 40þ years), sex, and EBV status of the
tumour, the findings remained essentially unchanged (data not
shown).
DISCUSSION
Our analyses of contemporaneously acquired primary care medical
data indicate that compared to matched controls, a substantially
higher proportion of people who develop Hodgkin’s lymphoma
visit the GP for an infection, a finding that is evident for at least a
decade prior to diagnosis. In contrast, there was little difference
between cases and controls in the proportion visiting for a non-
infectious problem until about a year before diagnosis when cases
showed a marked increase. We cannot, however, determine
whether the excess of clinically diagnosed infections is a
consequence of underlying immune abnormality or indeed,
whether the infections are playing a causal role. No single infection
stood out as being specifically associated with Hodgkin’s
lymphoma and no single event was identified within the 15 years
prior to diagnosis that might be associated with disease onset.
Although we cannot exclude the possible existence of a single
causal agent (possibly acting more than 15 years prior to
diagnosis), none was identified.
Large amounts of information on previous illnesses, including
infections, are routinely collected by medical practitioners
working in primary care. Although these data, which are
principally collected with the aim of documenting and monitoring
patient care, have been used in a limited way in a number of
aetiological studies (McKinney et al, 1991; Mann et al, 1993;
Chilvers et al, 1994; Ansell et al, 2005), their potential with
respect to describing symptom profiles is yet to be fully realised. A
critical advantage for aetiological and other studies – where the
sequence and timing of events is important – is that information
held in GP records is collected prior to the diagnosis of malignancy
and so have the advantage of being unaffected by recall and
reporting bias, having been recorded by the GP contempor-
aneously. The methods used for abstracting data from primary
care records were originally developed by the investigators
(PA and ER). Indeed, the use of clinical records permits a far
more precise characterisation of events preceding diagnosis than
is possible in studies that rely on self-report (Simpson et al,
2007).
As in other epidemiological studies, a fundamental but
simplistic distinction is made between Hodgkin’s lymphoma and
non-Hodgkin’s lymphoma which originates in concepts from the
early twentieth century. From an epidemiological perspective,
Hodgkin’s lymphoma appears to be distinctive, with an unusual
bimodal age distribution peaking in young adults and in older
people (www.hmrn.org). Hodgkin’s lymphoma also differs from
other types of lymphoma in having a female predominance in the
young adult age group. However, to examine the role of infectious
and immune factors in relation to Hodgkin’s lymphoma stratified
by age, sex or indeed by EBV status of the tumour, we would need
substantially larger numbers of cases than were available for
analysis here. Indeed, in this study as in many others, recruitment
was limited to a specific age range (16–69 years), which means,
because of the unusual age distribution of Hodgkin’s lymphoma,
many of the available cases were excluded.
However, it is apparent that CHL is a B-cell malignancy derived
from postgerminal centre cells. The defining feature of the tumour
cells is the loss of a mature B-cell phenotype but failure to
complete differentiation to plasma cells (Cossman et al, 1988, 1999;
Stein et al, 2001; Fan et al, 2003). The association of CHL with
other B-cell malignancies is emphasised by the occurrence of the
so-called composite lymphoma where CHL occurs in association
with follicular lymphoma, diffuse large B-cell lymphoma or B-
chronic lymphocytic leukaemia, and where both tumours can be
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Figure 1 Graph showing the number of cases (in red) and controls (in
blue) visiting the general practitioner at least once for a non-infectious
condition by individual month for the 15 years prior to diagnosis of
Hodgkin’s lymphoma, or pseudo-diagnosis in controls (excluding data from
the year prior to diagnosis).
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Figure 2 Graph showing the number of cases (in red) and controls (in
blue) visiting the general practitioner at least once for an infectious
condition by individual month for the 15 years prior to diagnosis of
Hodgkin’s lymphoma or pseudo-diagnosis in controls (excluding data from
the year prior to diagnosis).
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Cathcart-Rake et al, 1992; Jaffe et al, 1992; Kim, 1993; Kuppers
et al, 2001). Recent gene-expression studies have also shown that
at least some cases of CHL have a very similar pattern of gene
expression to mediastinal B-cell lymphoma. Both CHL and
mediastinal B-cell lymphoma affect the mediastinum and have a
female predominance in young adults leading to the suggestion
that they are derived from a specific population of thymic B cells
(Addis and Isaacson, 1986; Palanisamy et al, 2002; Rosenwald et al,
2003; Calvo et al, 2004). These studies demonstrate the importance
of considering CHL in the context of the epidemiology of B-cell
malignancies as a whole rather than as a separate entity. Ideally,
nodular lymphocyte predominant Hodgkin’s lymphoma should be
considered separately, although its rarity makes it difficult to
recruit the numbers of cases required for epidemiological studies.
In the future, high-quality, contemporaneously collected exposure
data, together with modern concepts of disease and accurate
diagnostic and demographic information, will play a key role in
addressing questions of pathogenesis of haematological malig-
nancies.
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